论文部分内容阅读
直接抗病毒药物(DAA)的研究是慢性丙型病毒性肝炎(CHC)治疗药物的重要研究方向,丙型肝炎病毒(HCV)NS3/4A丝氨酸蛋白酶(NS3/4A SP)对病毒蛋白前体加工成熟和病毒复制过程十分重要,是抗HCV治疗的理想靶点。本文重点综述NS3/4A丝氨酸蛋白酶抑制剂特拉泼维(telaprevir)和博赛泼维(boceprevir)治疗HCV感染的最新进展。
The study of direct antiviral drugs (DAAs) is an important research direction in the treatment of chronic hepatitis C virus (CHC). The hepatitis C virus (HCV) NS3 / 4A serine protease (NS3 / 4A SP) Mature and viral replication processes are important and are ideal targets for anti-HCV treatment. This article highlights the recent advances in the treatment of HCV infection with the NS3 / 4A serine protease inhibitors telaprevir and boceprevir.